Loading...
*  Ligand binding assay
"In situ drug-receptor binding kinetics in single cells: a quantitative label-free study of anti-tumor drug resistance". ... Thus, emphasizing the necessity to position assay designs in the correct manner both within, and between, each plate. The use ... Drugs that act upon these receptors are incredibly selective in order to produce required responses from signaling molecules. ... The effects of a drug are a result of their binding selectivity with macromolecule properties of an organism, or the affinity ...
*  Advanced Chemistry Development
International Union of Pure and Applied Chemistry Computer-Assisted Drug Design QSAR Structural Elucidation Scientific Data ... molecular property modelling and property-based design. The company is headquartered in Toronto, Ontario, Canada with direct ... and the capability to design or modify structures to attain a desired property profile. Proprietary computational algorithms ... "GALAS Modeling Methodology Applications in the Prediction of Drug Safety Related Properties" http://www.acdlabs.com/download/ ...
*  Drug design
The first is referred to as ligand-based drug design and the second, structure-based drug design. Ligand-based drug design (or ... Drug design, often referred to as rational drug design or simply rational design, is the inventive process of finding new ... the recent focus on rational drug design may limit the progress of drug discovery. Furthermore, the rational design of a drug ... The phrase "drug design" is to some extent a misnomer. A more accurate term is ligand design (i.e., design of a molecule that ...
*  Retrometabolic drug design
In the field of drug discovery, retrometabolic drug design is a strategy for the design of safer drugs using either a soft drug ... In retrometabolic drug design, metabolic reaction information of drugs is used to design parent drugs whose metabolism and ... Soft drugs and site-specific chemical delivery systems". Adv. Drug Res. 13: 255-331. Retrometabolism-based drug design and ... The concept of retrometabolic drug design encompasses two distinct approaches. One approach is the design of soft drugs (SDs), ...
*  Drug Design, Development and Therapy
... is a peer-reviewed medical journal covering research on drug design and development ...
*  Drug Design and Optimization Lab
... better known as "D2OL" was a Distributed Computing project with the goal of discovering drug ...
*  Donald Truhlar
... drug design; nanoparticle structure and energetics; and density functional theory, including the Minnesota Functionals. He has ...
*  Alcuronium chloride
CS1 maint: Untitled periodical (link) Martin-Smith M (1971), In: Ariens EJ (ed.), "Drug Design". Vol. 2. Academic Press. New ... Drugs. 4 (3-4): 163-226. doi:10.2165/00003495-197204030-00002. Thompson MA (1980). Br. J. Hosp Med. 23: 153. CS1 maint: ...
*  Biopolymers & Cell
Drug design; Biology of peptides, nucleoside derivatives and modified oligonucleotides Biopolym. Cell is issued bimonthly, with ...
*  Science and technology in Uzbekistan
... drug design; and technology, equipment and product design for the oil and gas and chemical industries. These fields were chosen ... This is designed to ensure that there is a demand for the research being undertaken and that the results will lead to products ... Each of these sectors tends to involve large companies equipped with design bureaux and laboratories. There are, however, also ...
*  Streptomyces misakiensis
Rational drug design. Boca Raton: CRC Press. ISBN 0-8493-7818-4. CS1 maint: Extra text: authors list (link) Ganten, edited by ... Zwieten, edited by Pieter A. van; Greenlee, William J. (1997). Antihypertensive drugs. Amsterdam, the Netherlands: Harwood ...
*  Heparinoid
"Heparin Oligosaccharides: New Analogues Development and Applications." Carbohydrates in Drug Design. New York: M. Dekker, 1997 ...
*  P. Karthe
He is known for his research in the fields of structural biology and drug designing. His studies have been documented by way of ... "Workshop on Advances in Computer Aided Drug Design" (PDF). vLife. August 2010. Retrieved 2018-01-24. "Past Conferences". www. ... Drug Design. 79 (1): 143-147. doi:10.1111/j.1747-0285.2011.01258.x. ISSN 1747-0285. Kumarevel, Thirumananseri; Fujimoto, Zui; ... others and has delivered invited speeches at many seminars which include the Workshop on Advances in Computer Aided Drug Design ...
*  Thiadiazoles
Drug Design. 81 (5): 557-576. doi:10.1111/cbdd.12125. ISSN 1747-0277. Wim Dehaen; Vasiliy A. Bakulev; Edward C. Taylor; ...
*  TAN-67
Drug Design and Discovery. 2001;17(4):325-30. PMID 11765135 Nagase H, Kawai K, Hayakawa J, Wakita H, Mizusuna A, Matsuura H, ... Rational drug design and synthesis of a highly selective nonpeptide delta-opioid agonist, (4aS*,12aR*)-4a-(3-hydroxyphenyl)-2- ... TAN-67 (SB-205,607) is a opioid drug used in scientific research that acts as a potent and selective δ-opioid agonist, ...
*  Autophosphorylation
"Design of potent IGF1-R inhibitors related to bis-azaindoles". Chemical Biology & Drug Design. 76 (2): 100-6. doi:10.1111/j. ... "Structure-based drug design enables conversion of a DFG-in binding CSF-1R kinase inhibitor to a DFG-out binding mode". ... "Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-pK a Polar Moiety". ACS ... "Structure-Guided Design of Group I Selective p21-Activated Kinase Inhibitors". Journal of Medicinal Chemistry. 58 (12): 5121-36 ...
*  Troponin C type 1
Drug Design. 85 (2): 99-106. doi:10.1111/cbdd.12381. PMC 4456024 . PMID 24954187. Wang X, Li MX, Sykes BD (Aug 2002). " ... Drug Discovery. 14: 313-28. doi:10.1038/nrd4554. PMID 25881969. Hwang PM, Cai F, Pineda-Sanabria SE, Corson DC, Sykes BD (Oct ... Lindert S, Li MX, Sykes BD, McCammon JA (Feb 2015). "Computer-aided drug discovery approach finds calcium sensitizer of cardiac ... Kleerekoper Q, Putkey JA (Aug 1999). "Drug binding to cardiac troponin C". The Journal of Biological Chemistry. 274 (34): 23932 ...
*  CDC42
Drug Design. 86 (4): 432-9. doi:10.1111/cbdd.12556. PMID 25777055. Bishop AL, Hall A (June 2000). "Rho GTPases and their ... "Targeting Cdc42 with the small molecule drug AZA197 suppresses primary colon cancer growth and prolongs survival in a ...
*  Cystatin
Drug Design. 72 (3): 217-24. doi:10.1111/j.1747-0285.2008.00693.x. PMID 18702630. Cystatin: a protein that flips out! QUite ...
*  ZK-93423
Drug Design and Discovery. 9 (2): 135-43. PMID 1338366. Cox ED, Diaz-Arauzo H, Huang Q, Reddy MS, Ma C, Harris B, McKernan R, ... ZK-93423 is an anxiolytic drug from the β-Carboline family, closely related to abecarnil. It is a nonbenzodiazepine GABAA ... It has anticonvulsant, muscle relaxant and appetite stimulating properties comparable to benzodiazepine drugs. ZK-93423 has ... use of the known structural requirements for benzodiazepine and beta-carboline binding in designing a novel, high-affinity ...
*  Metalloprotease inhibitor
Drug Design. 78 (2): 191-198. doi:10.1111/j.1747-0285.2011.01148.x. Brown, P. D. (1997). "Matrix metalloproteinase inhibitors ... In the design of these inhibitors, the basic protein backbone of collagen is maintained but the amide bond is replaced with a ... The drug is highly lipophilic and able to cross the blood brain barrier at higher doses. COL-3 accumulates in higher ... The primary goal of MMP inhibitor design is selectivity. The targeting of specific MMPs is expected to improve efficacy and ...
*  Serotonin releasing agent
Nichols DE, Marona-Lewicka D, Huang X, Johnson MP (1993). "Novel serotonergic agents". Drug Design and Discovery. 9 (3-4): 299- ... The designer drug 4-methylaminorex, which is an SNDRA and 5-HT2B agonist, has been reported to cause this effect as well. Many ... These drugs are serotonergic psychedelics, which is a consequence of their ability to activate the 5-HT2A receptor. αET and αMT ... A serotonin releasing agent (SRA) is a type of drug that induces the release of serotonin into the neuronal synaptic cleft. A ...
*  IKBKG
Craik DJ, Fairlie DP, Liras S, Price D (January 2013). "The future of peptide-based drugs". Chemical Biology & Drug Design. 81 ... A drug called NEMO Binding Domain (NBD) has been designed to inhibit activation of NF-κB. NBD is a peptide that acts by binding ... The NBD peptide was designed by identifying the amino acid binding sequence on IKK-α and IKK-β to which NEMO binds. A small ... Peptides as drugs lack membrane permeability, are poorly orally viable, and generally have lower metabolic stability than small ...
*  Anatole Klyosov
2012). Glycobiology and Drug Design. ACS symposium series (Vol 1102). Washington DC: American Chemical Society. Klyosov, A. A ... 2006). Carbohydrate Drug Design. ACS symposium series (Vol 932). Washington DC: American Chemical Society. ISBN 9780841239463. ... a company that was formed to use enzymes to add carbodydrates to existing cancer drugs to make them work better, and was caught ... that was founded to use enzymes to alter existing anticancer drugs via glycosylation. In 2008 he began publishing work about ...
*  Inonotus obliquus
Drug Design. 87 (4): 517-536. doi:10.1111/cbdd.12682. ISSN 1747-0285. ,access-date= requires ,url= (help) Zheng W, Miao K, Liu ...
*  Fairey Prince (H-16)
The Prince P.16 was a radical design by Captain A.G. Forsyth who was the Fairey company's chief engine designer. The Prince was ... and the drag of both engine nacelles can be eliminated and combined within the cross-section of the fuselage. Fairey Battle P. ... The Fairey P.16 Prince was a British experimental 1,500 hp (1,118 kW) 16-cylinder H-type aircraft engine designed and built by ... Unfortunately, a conventional twin could not be designed so that it came within the size limits for aircraft carrier use on the ...
*  Acrosin
"Fragment-Based Design of Novel Quinazolinon Derivatives as Human Acrosin Inhibitors". Chemical Biology & Drug Design. 81 (4): ... Further consistent with this structural hypothesis is the knowledge that suramin - a polysulfated drug (with substantial ... compound for design of new anti-fertility agents". Mol. Hum. Rep. 2 (8): 597-605. doi:10.1093/molehr/2.8.597. Welker B, ...